Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15545780 | 1.00 | FFAR3 (0.38) | FFAR3LCKFYNLMNATHRB | |
| SCHEMBL28640407 | 0.84 | FFAR3 (0.35) | FFAR3LCKFYNTHRBFNTA | |
| SCHEMBL15546434 | 0.76 | — | — | |
| SCHEMBL10604698 | 0.76 | — | — | |
| SCHEMBL26929225 | 0.76 | — | — | |
| SCHEMBL15546019 | 0.76 | — | — | |
| SCHEMBL8471579 | 0.76 | — | — | |
| SCHEMBL869357 | 0.76 | — | — | |
| SCHEMBL14690127 | 0.73 | CA1 (0.36) | FFAR3LCKFYN | |
| SCHEMBL10661655 | 0.73 | FFAR3 (0.55) | FFAR3LCKFYNLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150196585-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | VIFOR (INTERNATIONAL) LTD. (CH) | 2015-07-16 | — | — | US | disclosed |
| US-20150183908-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | VIFOR (INTERNATIONAL) LTD. (CH) | 2015-07-02 | — | — | US | disclosed |
| EP-2874633-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS | Relypsa, Inc. (US) | 2015-05-27 | — | — | EP | disclosed |
| WO-2014015240-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS | SORBENT THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2014015244-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS | SORBENT THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183908-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | PICALM, ORAI1, KCNN3 | FFAR3 1640/4885LCK 740/4885FYN 3328/4885 |
| US-20150196585-A1 | COMPOSITIONS COMPRISING CROSSLINKED CATION-BINDING POLYMERS AND USES THEREOF | SSB, PARG, HLA-DRB1 | FFAR3 1128/4885LCK 491/4885FYN 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.